---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-019011"
form_type: "8-K"
ticker: "GANX"
cik: "0001819411"
company_name: "Gain Therapeutics, Inc."
filed_at: "2023-11-14T23:59:59+00:00"
generated_at: "2026-06-08T03:56:31.044132+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Gain Therapeutics Q3 net loss $4.7M; Phase 1 trial of GT-02287 underway

## Summary
- Net loss $4.7M ($0.37/sh) vs $4.6M ($0.38/sh) in Q3 2022; R&D expense rose $0.4M to $2.4M.
- Cash, cash equivalents and marketable securities $12.3M; sufficient into Q3 2024.
- Phase 1 clinical trial of GT-02287 initiated in Australia; dose escalation ongoing.
- Completion of single ascending dose part expected late Q4 2023/early Q1 2024; multiple ascending dose expected Q2 2024.
- Preclinical data presented at Parkinson's congress showed GT-02287 reduced NfL biomarker and motor dysfunction.

## SEC filing metadata
- accession: 0001558370-23-019011
- form_type: 8-K
- ticker: GANX
- cik: 0001819411
- company_name: Gain Therapeutics, Inc.
- filed_at: 2023-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1819411/000155837023019011/0001558370-23-019011-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1819411/000155837023019011/ganx-20231114x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-019011
- JSON: https://secwatch.observer/filing/0001558370-23-019011.json
- Plain text: https://secwatch.observer/filing/0001558370-23-019011.txt

## Key facts
- Earnings Releases
  Gain Therapeutics, Inc. reported third quarter ended September 30, 2023 results: net income $4.7 million, or $0.37 per share basic and diluted, EPS $0.37 per share basic and diluted.
  - Period: third quarter ended September 30, 2023
  - Net income: $4.7 million, or $0.37 per share basic and diluted
  - EPS: $0.37 per share basic and diluted
  - Result: reported results
  source text: On November 14, 2023, Gain Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the third quarter ended September 30, 2023, and business update.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1819411/000155837023019011/0001558370-23-019011-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.